March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Tivozanib, A Highly Potent Inhibitor Of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, Has Antiangiogenic Properties On Experimental Choroidal Neovascularization
Author Affiliations & Notes
  • Seungbum Kang
    Department of Ophthalmology and Visual Science, Deajeon St. Mary's Hospital, College of Medicine, Catholic University of Korea, Republic of Korea
  • Young-Jung Roh
    Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, College of Medicine, Catholic University of Korea, Republic of Korea
  • In-Beom Kim
    Department of Anatomy, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  Seungbum Kang, None; Young-Jung Roh, None; In-Beom Kim, None
  • Footnotes
    Support  Clinical Research Institute Grant (CMCDJ-P-2011-2) funded by The Catholic University of Korea
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3017. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Seungbum Kang, Young-Jung Roh, In-Beom Kim; Tivozanib, A Highly Potent Inhibitor Of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, Has Antiangiogenic Properties On Experimental Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3017. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the effects of tivozanib, an inhibitor of vascular endothelial growth factor receptors, on experimental choroidal neovascularization (CNV) model.

Methods: : C57BL/6 mice were treated with tivozanib (1 mg/kg/day) or vehicle at the onset (day 0) of study. Experimental CNV was induced by laser photocoagulation the following day. In other groups of mice, tivozanib or vehicle treatment was started 7 days after the laser application to determine the effect of the drug on established CNV. After 14 days, the extent of CNV was assessed from choroidal flat mounts perfused with fluorescein-labeled dextran. Immunofluorescence staining with isolectin IB4 was also used to quantify the CNV lesions.

Results: : Tivozanib suppressed the development of CNV lesions, reducing the area by 80.7 % compared to vehicle-treatment (p < 0.001). Tivozanib caused a significant regression of established CNV, reducing the area by 67.7 % compared to vehicle-treatment (p < 0.001). Isolectin IB4-labeled area was smaller in the tivozanib-treated mice compared to the vehicle-treatment (p < 0.001).

Conclusions: : Tivozanib effectively inhibits the progression of CNV in mice CNV model. These results suggest that tivozanib could constitute a therapeutic alternative for the treatment of neovascular AMD.

Keywords: choroid: neovascularization • vascular endothelial growth factor • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×